Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Regeneron reported $3.68 billion in revenue for Q2 2025, a year-over-year increase of 3.6%, with an EPS of $12.89 compared to $11.56 a year ago, exceeding Zacks Consensus Estimates for both revenue and EPS [1] Revenue Performance - Eylea (Aflibercept) in the US generated $1.15 billion, surpassing the average estimate of $1.03 billion, but reflecting a year-over-year decline of 25.2% [4] - Praluent (alirocumab) in the US reported revenues of $65.8 million, exceeding the average estimate of $54.57 million, with a year-over-year increase of 17.3% [4] - Total net product sales amounted to $1.63 billion, compared to the average estimate of $1.46 billion, representing a year-over-year decline of 15% [4] - Collaboration revenues totaled $1.86 billion, exceeding the average estimate of $1.73 billion, with a year-over-year increase of 22.1% [4] - Total Bayer collaboration revenue was $415 million, surpassing the estimate of $388.54 million, reflecting a year-over-year increase of 10.6% [4] - Total Sanofi collaboration revenue reached $1.44 billion, exceeding the average estimate of $1.36 billion, with a year-over-year increase of 26% [4] Stock Performance - Regeneron's shares returned -0.4% over the past month, while the Zacks S&P 500 composite increased by 2.3%, indicating potential underperformance in the near term [3]